Alzyn LLC Names Christos Efessiou Chief Marketing Officer

Monday, October 29, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Alzyn, LLC. is an innovative consumer health and wellness company with a novel proprietary technology which uniquely enables the delivery of key nutrients that have been shown to protect brain cell health

ST. PETERSBURG, Fla., Oct. 29, 2018 /PRNewswire-PRWeb/ -- Alzyn LLC, a St Petersburg Florida

based innovative consumer health and wellness company focusing on protecting aging brain cells, has appointed Christos Efessiou, a partner at Newport Board Group, as its Chief Marketing Officer.

Speaking on behalf of the Board of Directors, Don Rosenkoetter Founder, Interim President, and Partner at Newport Board Group said "Chris is a proven senior executive with extensive expertise in developing, leading and profitably commercializing 36 new products into the global market. Among his many marketing successes was the 2005 launch of Mucinex into the professional market segment, which established a new standard. His knowledge, experience and passion for our endeavor will help ensure a commercial success." Christos's background includes senior leadership positions at Strategic Pharmaceutical Advisors, Alergos Pharmaceuticals, Strategic BioSciences, and Strategic Implications International, now part of Cardinal Health.

About Alzyn Alzyn, LLC. is an innovative consumer health and wellness company with a novel proprietary technology which uniquely enables the delivery of key nutrients that have been shown to protect brain cell health. Healthy brain cells are known to defend against diminished mental capacity. The company is being advised by the Newport Board Group.

Alzyn's novel technology was jointly developed by Dr. Ewa Bienkiewicz, Associate Professor of Biomedical Sciences at Florida State University's College of Medicine and Associate Editor of The Journal of Alzheimer's Disease, with TD Solutions Corp., a Palm Beach Gardens company. The approach is to couple four GRAS ingredients that have demonstrated favorable and statistically significant change on several factors impacting disease-related cognitive loss (including tau and beta amyloids,) with a unique delivery system that is able to carry these ingredients across the blood-brain barrier.

The prospect of bringing this technology to the millions of aging Americans who are losing their cognitive abilities creates tremendous passion and energy among our team.

Contact: Don Rosenkoetter Interim President don.rosenkoetter@newportboardgroup.com (617) 461-6654

SOURCE Alzyn LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store